Bristol Myers Squibb
Search results
Learn how Celgene, a global biopharmaceutical company, is committed to improving the lives of patients worldwide by delivering truly innovative and life-changing treatments. Explore the therapies for Hematology, Oncology, Inflammation and Immunology and the medical research to help people live longer, better, and healthier.
Footnotes / references. [1] Celgene Corporation is a pharmaceutical company that makes cancer and immunology drugs. Its major product is Revlimid ( lenalidomide ), which is used in the treatment of multiple myeloma, and also in certain anemias.
To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID ® (thalidomide), POMALYST ® (pomalidomide), REVLIMID ® (lenalidomide) and generic lenalidomide.
Jan 3, 2019 · Four in hematology, luspatercept, liso-cel (JCAR017), bb2121 and fedratinib. These launches leverage the combined commercial capabilities of the two companies and will broaden and enhance Bristol-Myers Squibb’s market position with innovative and differentiated products.
Nov 20, 2019 · Bristol-Myers Squibb Company (NYSE:BMY) announced today that it has completed its acquisition of Celgene Corporation (NASDAQ:CELG) following the receipt of regulatory approval from all government authorities required by the merger agreement and, as announced on April 12, 2019, approval by Bristol-Myers Squibb and Celgene stockholders.
At Celgene, we seek to deliver truly innovative and life-changing medicines that make a difference in the lives of patients worldwide, reduce burden on healthcare systems and help economies grow.
Celgene is committed to responsible and transparent sharing of clinical trial data with patients, healthcare practitioners and independent researchers for the purpose of improving scientific and medical knowledge as well as fostering innovative treatment approaches.
